Compound Radar

Catalyst Pharmaceuticals Inc (CPRX) Stock Analysis

United States · Healthcare / Biotechnology

Price $31.49
Market cap $3.85B
Entry status Watch $25.61–$27.19

Last updated Aug 30, 2026

Health Check

Last analyzed Sep 7, 2026

81
81/100 Elite Quality
  • Financial Health 70
  • Profitability 95
  • Business Quality 75
  • Balance Sheet 65
  • Cash Flow 80

Why this rating?

Health 81/100 — Elite Quality

Strongest Profitability 95/100
Softest Balance Sheet 65/100
Watch

Worth tracking, but timing is mixed — not a clear setup yet.

Company overview

Catalyst Pharmaceuticals Inc (CPRX) is a Biotechnology company in the Healthcare sector. Compound Radar rates Catalyst Pharmaceuticals Inc 81/100 (Elite Quality) due to high business quality, steady revenue growth, and manageable leverage.

Investment profile

  • Quality High
  • Growth Moderate
  • Balance Sheet Adequate
  • Valuation Attractive

Financial highlights

Valuation

  • P/E 18.2
  • Forward P/E 9.9
  • EV/Revenue 5.19

Profitability

  • Revenue Growth 5.6%
  • Gross Margin 84.0%
  • Operating Margin 49.0%
  • Net Margin 37.1%
  • ROE 24.5%

Financial strength

  • Cash $755.86M
  • Debt $2.68M
  • Net Cash $753.18M
  • Free Cash Flow $208.61M
  • Current Ratio 7.1

Similar companies

Peers in Biotechnology, ranked by Financial Health.

Company Ticker
Price Current price

Latest quoted price for the name. Helps anchor the setup in today’s market level.

Health Entry

View all in Biotechnology →

FAQ

How Compound Radar scores and tracks Catalyst Pharmaceuticals Inc (CPRX).

View Methodology & FAQ →